Collecting duct carcinoma: Epidemiology, clinical characteristics and survival.
暂无分享,去创建一个
F. Saad | A. Briganti | S. Shariat | P. Karakiewicz | A. Kapoor | O. de Cobelli | Z. Tian | D. Tilki | A. Tafuri | C. Terrone | M. Cerruto | A. Panunzio | F. Barletta | A. Antonelli | S. Tappero | L. Hohenhorst | M. Piccinelli | F. Chun | C. Cano Garcia
[1] F. Saad,et al. Life expectancy in metastatic urothelial bladder cancer patients according to race/ethnicity , 2022, International Urology and Nephrology.
[2] Jiaqiao Zhang,et al. Impact of Treatment Modalities on Prognosis in Patients With Renal Collecting Duct Carcinoma: A Population-Based Study , 2022, Frontiers in Oncology.
[3] L. Mariani,et al. Cabozantinib as First-line Treatment in Patients With Metastatic Collecting Duct Renal Cell Carcinoma: Results of the BONSAI Trial for the Italian Network for Research in Urologic-Oncology (Meet-URO 2 Study). , 2022, JAMA oncology.
[4] C. Porta,et al. Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma , 2022, Cancer.
[5] K. Gong,et al. Collecting duct carcinoma of the kidney: Analysis of 74 cases from multiple centers. , 2022, Urology.
[6] R. Garje,et al. Patient Characteristics and Survival Outcomes of Non-Metastatic, Non-Clear Cell Renal Cell Carcinoma , 2022, Frontiers in Oncology.
[7] Paras H Shah,et al. Collecting duct carcinoma: A single-institution retrospective study. , 2021, Urologic oncology.
[8] Wenquan Zhou,et al. Incidence, Clinical Characteristics, and Survival of Collecting Duct Carcinoma of the Kidney: A Population-Based Study , 2021, Frontiers in Oncology.
[9] S. Pal,et al. "Collecting duct carcinoma of the kidney: diagnosis and implications for management". , 2021, Urologic oncology.
[10] F. Saad,et al. Life expectancy in metastatic prostate cancer patients according to racial/ethnic groups , 2021, International journal of urology : official journal of the Japanese Urological Association.
[11] F. Saad,et al. Renal Cell Carcinoma: Comparison Between Variant Histology and Clear Cell Carcinoma Across all Stages and Treatment Modalities. , 2020, The Journal of urology.
[12] H. Miyake,et al. Complete response to combination therapy with nivolumab and ipilimumab for metastatic collecting duct carcinoma of the kidney , 2019, International Cancer Conference Journal.
[13] M. Colecchia,et al. Collecting ducts carcinoma: An orphan disease. Literature overview and future perspectives. , 2019, Cancer treatment reviews.
[14] W. Tu,et al. Frequency, incidence and survival outcomes of clear cell renal cell carcinoma in the United States from 1973 to 2014 , 2019, Medicine.
[15] Lorenzo Marconi,et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update. , 2019, European urology.
[16] Y. Nagashima,et al. Nivolumab therapy for metastatic collecting duct carcinoma after nephrectomy , 2018, Medicine.
[17] F. Zhou,et al. Sorafenib in combination with gemcitabine plus cisplatin chemotherapy in metastatic renal collecting duct carcinoma: A prospective, multicentre, single-arm, phase 2 study. , 2018, European journal of cancer.
[18] A. Briganti,et al. Survival after Cytoreductive Nephrectomy in Metastatic Non-clear Cell Renal Cell Carcinoma Patients: A Population-based Study. , 2017, European urology focus.
[19] A. Briganti,et al. Survival of metastatic renal cell carcinoma patients continues to improve over time, even in targeted therapy era , 2017, International Urology and Nephrology.
[20] A. Roychoudhury,et al. Collecting duct carcinoma of the kidney: Disease characteristics and treatment outcomes from the National Cancer Database. , 2017, Urologic oncology.
[21] P. Humphrey,et al. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. , 2016, European urology.
[22] Y. Allory,et al. Triple combination of bevacizumab, gemcitabine and platinum salt in metastatic collecting duct carcinoma. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[23] C. Stief,et al. Impact of clinical and histopathological parameters on disease specific survival in patients with collecting duct renal cell carcinoma: development of a disease specific risk model. , 2013, The Journal of urology.
[24] F. Montorsi,et al. Conditional survival after nephrectomy for renal cell carcinoma (RCC): changes in future survival probability over time , 2013, BJU international.
[25] T. Choueiri,et al. Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. , 2012, The Lancet. Oncology.
[26] J. Wright,et al. Effect of collecting duct histology on renal cell cancer outcome. , 2009, The Journal of urology.
[27] G. Hédelin,et al. Conditional relative survival of cancer patients and conditional probability of death , 2009, Cancer.
[28] S. Culine,et al. Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d'Etudes des Tumeurs Uro-Génitales) study. , 2007, The Journal of urology.
[29] N. Rioux-Leclercq,et al. Collecting duct renal cell carcinoma: a matched analysis of 41 cases. , 2007, European urology.
[30] R. Motzer,et al. Targeted therapy for metastatic renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] S. Naito,et al. Collecting duct (Bellini duct) renal cell carcinoma: a nationwide survey in Japan. , 2006, The Journal of urology.
[32] R. Tardanico,et al. The collecting duct carcinoma of the kidney: a cytogenetical study. , 2003, European urology.